

Qiagen, Inovio expand collaboration to develop NGS CDx

March 10, 2021—[Qiagen](#) and [Inovio Pharmaceuticals](#) have extended their partnership with a new agreement to develop liquid-biopsy-based companion diagnostic products based on next-generation sequencing technology to complement Inovio's therapies.

The initial project focuses on the co-development of a diagnostic test that identifies women who are most likely to benefit from clinical use of VGX-3100, Inovio's immunotherapy to treat advanced cervical dysplasia associated with human papillomavirus. The assay will be developed for use on the Illumina NextSeq 550Dx platform, the first development based on a partnership Qiagen and Illumina signed in October 2019.

VGX-3100 is Inovio's late-stage DNA immunotherapy candidate. It is currently in two phase three trials (REVEAL 1 and REVEAL 2), with the potential to become the first nonsurgical treatment for advanced precancerous cervical lesions associated with HPV-16 and HPV-18.